

Resource Summary Report

Generated by [dkNET](#) on Sep 5, 2026

KLM-1

RRID:CVCL_5146

Type: Cell Line

Proper Citation

RRID:CVCL_5146

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5146

Proper Citation: RRID:CVCL_5146

Description: Cell line KLM-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pancreatic ductal adenocarcinoma

Defining Citation: [PMID:8872523](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Characteristics: Established after 2 rounds of injection of cell suspensions of subcutaneous tumors arising from PK-1 in BALB/c nude mice., Population: Japanese., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KLM-1

Synonyms: KLM1

Cross References: CLO:CLO_0050104, EFO:EFO_0006610, ArrayExpress:E-MTAB-2706, BioSample:SAMN03472943, cancercellines:CVCL_5146, Cell_Model_Passport:SIDM01632, DepMap:ACH-001101, EGA:EGAS00001000610, FANTOM5_SSTAR:10438-106E6, GEO:GSM888285, IARC_TP53:30097, PharmacDB:KLM1_751_2019, Progenetix:CVCL_5146, RCB:RCB2138, TKG:TKG 0490, Wikidata:Q54900025

ID: CVCL_5146

Hierarchy: cvcl_4717

Record Creation Time: 20220427T220704+0000

Record Last Update: 20260904T014505+0000

Ratings and Alerts

No rating or validation information has been found for KLM-1.

No alerts have been found for KLM-1.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Safari M, et al. (2026) Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 84, 101312.

Cunniff PJ, et al. (2025) KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. Nature communications, 16(1), 9996.

Zhu Y, et al. (2025) Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer. Frontiers in immunology, 16, 1524899.

Umemura K, et al. (2025) PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microenvironment in Pancreatic Cancer. Molecular cancer research : MCR.

Somerville TD, et al. (2020) Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation. eLife, 9.